How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Lea Bucher
Advertisement
Lea Bucher is Principal at Executive Insight.
Articles by Lea Bucher
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
3
Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint
4
Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products
5
